These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 6968164)

  • 21. Antinuclear antibodies.
    Rheum Dis Clin North Am; 1992 May; 18(2):283-505. PubMed ID: 1626071
    [No Abstract]   [Full Text] [Related]  

  • 22. Antinuclear antibodies.
    Felt J
    Minn Med; 1982 Jan; 65(1):39-40. PubMed ID: 7040935
    [No Abstract]   [Full Text] [Related]  

  • 23. Recognizing the dense fine speckled/lens epithelium-derived growth factor/p75 pattern on HEP-2 cells: not an easy task! Comment on the article by Mariz et al.
    Bizzaro N; Tonutti E; Villalta D
    Arthritis Rheum; 2011 Dec; 63(12):4036-7; author reply 4037-8. PubMed ID: 22127717
    [No Abstract]   [Full Text] [Related]  

  • 24. Pattern on the antinuclear antibody-HEp-2 test is a critical parameter for discriminating antinuclear antibody-positive healthy individuals and patients with autoimmune rheumatic diseases.
    Mariz HA; Sato EI; Barbosa SH; Rodrigues SH; Dellavance A; Andrade LE
    Arthritis Rheum; 2011 Jan; 63(1):191-200. PubMed ID: 20954189
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anticentromere antibodies: clinical and biological significance.
    Fritzler MJ; Ayer LM
    J Rheumatol; 1982; 9(4):489-90. PubMed ID: 6982333
    [No Abstract]   [Full Text] [Related]  

  • 26. [Antinuclear factors. I. Clinical and immuno-pathologic significance].
    Peltier AP
    Presse Med (1893); 1970 Oct; 78(45):1969-73. PubMed ID: 4098224
    [No Abstract]   [Full Text] [Related]  

  • 27. [Antinuclear antibodies and disease specificity].
    Ersöz US D
    Mikrobiyol Bul; 1992 Oct; 26(4):379-89. PubMed ID: 1435370
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Antinuclear antibodies in rheumatology].
    Zuber M
    Z Rheumatol; 1994; 53(6):327-34. PubMed ID: 7871904
    [TBL] [Abstract][Full Text] [Related]  

  • 29. How to use... antinuclear antibodies in paediatric rheumatic diseases.
    Weaver LK; Behrens EM
    Arch Dis Child Educ Pract Ed; 2013 Apr; 98(2):64-70. PubMed ID: 23492397
    [No Abstract]   [Full Text] [Related]  

  • 30. Thought barriers to understanding rheumatic diseases.
    Holman HR
    Arthritis Rheum; 1994 Nov; 37(11):1565-72. PubMed ID: 7980665
    [No Abstract]   [Full Text] [Related]  

  • 31. [Antinuclear factors. Clinical and humoral correlations; diagnostic importance].
    Purice S; Gheorghiu M; Ghelerter L; Drăgoi T
    Med Interna (Bucur); 1969 Oct; 21(10):1205-40. PubMed ID: 4189145
    [No Abstract]   [Full Text] [Related]  

  • 32. Anticentromere antibodies--clinical correlates.
    Wade JP; Sack B; Schur PH
    J Rheumatol; 1988 Dec; 15(12):1759-63. PubMed ID: 3265957
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ANAs and antibodies to DNA: their use in clinical diagnosis.
    Reichlin M
    Bull Rheum Dis; 1993 Nov; 42(7):3-5. PubMed ID: 8173647
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Arthritis].
    Medicina (B Aires); 1978; 38(6 Pt 2):866-74. PubMed ID: 312417
    [No Abstract]   [Full Text] [Related]  

  • 35. [Significance of selected laboratory findings in rheumatic diseases. 2: The second step in diagnosis].
    Apostoloff E; Hiepe F; Mielke F
    Z Arztl Fortbild (Jena); 1987; 81(9):409-12. PubMed ID: 3498267
    [No Abstract]   [Full Text] [Related]  

  • 36. Antinuclear antibodies.
    Faber V; Feltkamp TE; Räsänen J
    Scand J Rheumatol Suppl; 1975; 12():121-2. PubMed ID: 1084553
    [No Abstract]   [Full Text] [Related]  

  • 37. Autoantibodies to chromosomal domains in rheumatic diseases.
    Martin L; Cusano R; Kingwell B; Fritzler MJ; Rattner JB
    J Clin Lab Immunol; 1990 Jun; 32(2):73-8. PubMed ID: 1967042
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence and characterization of novel pANCA, antibodies to the high mobility group non-histone chromosomal proteins HMG1 and HMG2, in systemic rheumatic diseases.
    Uesugi H; Ozaki S; Sobajima J; Osakada F; Shirakawa H; Yoshida M; Nakao K
    J Rheumatol; 1998 Apr; 25(4):703-9. PubMed ID: 9558172
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Our experience in the study of nuclear and antinuclear constituant antibodies in rheumatology].
    Kahn MF; Dryll A; de Seze S
    J Belge Rhumatol Med Phys; 1967; 22(4):217-30. PubMed ID: 4185873
    [No Abstract]   [Full Text] [Related]  

  • 40. Antibodies to hnRNPs in patients with a systemic rheumatic disease with no antibodies to extractable nuclear antigens or dsDNA.
    De Beéck KO; Vermeersch P; Verschueren P; Westhovens R; Mariën G; Blockmans D; Bossuyt X
    Rheumatology (Oxford); 2012 Aug; 51(8):1515-6. PubMed ID: 22661555
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.